Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kristina Harpe

Nurse Practitioner, Critical Care Medicine Atlanta, GA Nurse Practitioner

NPI 1497295083 CMS profile 10734907

550 Peachtree St Ne, Davis Fischer Building, Office 3245A, Atlanta, GA 30308

Open in the dashboard

General payments

$1,295

66 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristina Harpe of Atlanta, GA is reported in the CMS Open Payments database as having received $1,295 across 66 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $523 24
2024 General $575 31
2023 General $182 10
2022 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristina Harpe
  • Nurse Practitioner, Critical Care Medicine median
  • Middle half of Nurse Practitioner, Critical Care Medicine
  • National median

In program year 2025, general payments to Kristina Harpe were reported at $523. Among 524 Nurse Practitioner, Critical Care Medicine profiles paid that year, the median was $119 and the middle half received between $34 and $300.

Show as a table
Year Kristina Harpe Nurse Practitioner, Critical Care Medicine median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $103 $27–$237 $132
2022 $15 $125 $44–$255 $149
2023 $182 $116 $32–$261 $160
2024 $575 $122 $32–$292 $164
2025 $523 $119 $34–$300 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Novo Nordisk Inc $286 14 payments
  2. Lilly USA, LLC $173 15 payments
  3. Shield Therapeutics Inc $141 6 payments
  4. GlaxoSmithKline, LLC. $136 3 payments
  5. AstraZeneca Pharmaceuticals LP $70 4 payments
  6. Astellas Pharma US Inc $64 3 payments
  7. Pfizer Inc. $50 3 payments
  8. Boston Scientific Corporation $37 1 payment
  9. Sumitomo Pharma America, Inc. $33 2 payments
  10. Amgen Inc. $32 2 payments
  11. Other $274 13 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,281 65 payments
  2. Entertainment $14 1 payment
Products named General payments · program years 2022–2025
  1. RYBELSUS $218 11 payments
  2. Ozempic $218 11 payments
  3. MOUNJARO $153 13 payments
  4. ACCRUFER $141 6 payments
  5. ZEPBOUND $76 8 payments
  6. Wegovy $69 3 payments
  7. Veozah $64 3 payments
  8. TRULICITY $47 3 payments
  9. WATCHMAN Access System $37 1 payment
  10. FARXIGA $35 2 payments
  11. Other $626 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

1,293

Median for Nurse Practitioner: 389

Drug cost

$201,404

Median for Nurse Practitioner: $21,885

Branded share of claims

17.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 27 $49,459
Jardiance Empagliflozin Brand 28 $40,875
Mounjaro Tirzepatide Brand 16 $32,281
Farxiga Dapagliflozin Propanediol Brand 23 $31,102
Eliquis Apixaban Brand 20 $15,707
Gemtesa Vibegron Brand 15 $9,954
Linzess Linaclotide Brand 11 $8,756
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $2,966
Celecoxib Generic 41 $1,194
Atorvastatin Calcium Generic 104 $812

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $80
$80 16 —
ZEPBOUND
  • Lilly USA, LLC $43
$43 — —
Veozah
  • Astellas Pharma US Inc $37
$37 — —
Auvelity
  • Axsome Therapeutics, Inc. $26
$26 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

66 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record